Malignant tumors have been gradually replaced cardiovascular cerebrovascular diseases as the major disease serious hazard to human health. It ranks second in diseases which cause deaths. Chinese cancer mortality shows a clear upward trend. It ranks a high level in the world. The cancer drug glutathione market has also become the focus with great attention from various pharmaceutical companies. Its market size is far more than the growth rate of other drugs. Today, various types of therapeutic drugs and immune adjuvant drugs are over 200 kinds. In the therapy, cytotoxic antibody class and adjuvant therapy drugs become the three pillars in oncology markets and they become indispensable.

In Chinese hospital drug market, the sales volume of anticancer drugs in recent years has been steady growth, especially between 2003 and 2005. The CAGR is 24.53%. In 2006, subjecting to the impact of the policy environment of controlling drug sales and commercial bribery, anticancer drugs market size has much slower growth. It increased by only 11.10%. 2007-2009 sales volume continued rapid growth in 2009 broke through 40 billion RMB, 40.5 billion RMB with an increase of 28.57%. Between 2009 to 2010, China's overall anti-cancer drug market size is $ 25 billion / year. It is the second largest in share o fall kinds of drugs in China just after anti-infective therapy market.

In recent years, the market size of the plants and natural medicine irinotecan continues to expand; antibody drugs, hormones, anti-metabolite class is growing rapidly, the formation of the plant, other classes, and three classes of anti-metabolic pattern as the main drug market. Market share is 74%. Alkylating agent class, the class of antibiotics and platinum market share is shrinking.

At present, the type of drug is still cytotoxic drugs as the main pillar, accounting for 70% of the total share of targeted molecular agents (antibodies, tyrosine kinase inhibitor) has risen to 17%. Hormone and compound Chinese medicine accounted for 13% share in the share of cytotoxic drugs and gradually lower, in addition to the factors of falling prices, new drugs in recent years less than the targeted molecule drug related. To expand the share of targeted molecular drugs become inevitable, while subject to price too high, but hindered the clinical, send in affordable drugs to patients, as well as the listing of new varieties.

In 110 generic drugs of 2009, leading drugs amount of 20 kinds of drugs accounted for 73.75% of the overall share. The first two are docetaxel and paclitaxel. They all belong to the herbal class. The third is: oxaliplatin. In addition, the antibody drugs are lined up in the top 20: the rituximab group of natalizumab and the secretary row rank the 7th and 11th.

In recent years, the global antineoplastic R & D is extremely active. There are diverse categories in study. The research and development of molecular targeted anticancer drug has a dominant position. New drugs with high biological activity and low toxicity are produces for new targets and they are continuously developed. Structure and mechanism-based drug design has become a mainstream form for anticancer drugs discovers. In 2010, there are more than 470 anti-tumor drugs in clinical studies involving a total of more than 2760 clinical study. The phase III clinical trials are 231 involving the new drug over 50.Source:http://www.cospcn.com